Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer

Απλή σελίδα τεκμηρίου
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorSamantas, E.en
dc.contributor.authorKalofonos, H.en
dc.contributor.authorSkarlos, D.en
dc.contributor.authorMakatsoris, T.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorBamias, A.en
dc.contributor.authorDimopoulos, M. A.en
dc.contributor.authorKosmidis, P.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T18:58:58Z
dc.date.available2015-11-24T18:58:58Z
dc.identifier.issn0344-5704-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19329
dc.rightsDefault Licence-
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic useen
dc.subjectBone Neoplasms/drug therapy/secondaryen
dc.subjectBrain Neoplasms/drug therapy/secondaryen
dc.subjectCamptothecin/administration & dosage/adverse effects/analogs & derivativesen
dc.subjectCarcinoma, Small Cell/*drug therapy/pathologyen
dc.subjectCisplatin/administration & dosage/adverse effectsen
dc.subjectEtoposide/administration & dosage/adverse effectsen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectLiver Neoplasms/drug therapy/secondaryen
dc.subjectLung Neoplasms/*drug therapy/pathologyen
dc.subjectMaleen
dc.subjectMaximum Tolerated Doseen
dc.subjectMiddle Ageden
dc.subjectSurvival Analysisen
dc.titlePhase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung canceren
heal.abstractAIM: The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. METHODS: Successive cohorts of AS-SCLC patients were treated with irinotecan administered as a single 1-h infusion in combination with fixed doses of cisplatin (20 mg/m(2)) and etoposide (75 mg/m(2)), both given for three consecutive days (ECI regimen). Irinotecan dose was escalated from 60 mg/m(2) by 40-mg/m(2) increments. At mid-step between the maximum tolerated dose (MTD) and the previous dose level, patients were randomized for the day of administration of irinotecan (day 1 vs day 3). RESULTS: A total of 36 AS-SCLC patients received 166 courses of treatment at four dose levels. The MTD of irinotecan was 140 mg/m(2) (three dose-limiting toxicities, DLTs), and the recommended optimal dose (ROD) 120 mg/m(2) (two DLTs). DLTs were febrile neutropenia and grade 3 diarrhea. Other toxicities were mild. No difference in toxicity was seen between the two time schedules. A 77% (95% CI 63.25-90.75%) response rate was recorded among 31 evaluable patients and the median survival was 12 months. CONCLUSIONS: The ECI regimen was well tolerated and showed considerable activity in patients with AS-SCLC. Phase II/III evaluation is ongoing.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1007/s00280-004-0994-8-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/15959778-
heal.identifier.secondaryhttp://www.springerlink.com/content/ll12p168562p7l16/fulltext.pdf-
heal.journalNameCancer Chemother Pharmacolen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ